Medindia

X

The Growth in Medical Device and Technology Markets

Monday, October 31, 2016 Medical Gadgets J E 4
Advertisement

NEW YORK, October 31, 2016 /PRNewswire/ --

The medical device and technology markets are facing global challenges like escalating consolidation, conflicts with insurance companies, as well as political and economic uncertainties in China and Europe. Despite these challenges, a research report by Evaluate Ltd, released at AdvaMed, estimates that the medical device and technology markets will grow 5% or more annually until 2022 and reaching nearly $530 billion. Medovex Corp. (NASDAQ: MDVX), Boston Scientific Corporation (NYSE: BSX), Zimmer Biomet Holdings Inc. (NYSE: ZBH), Medtronic PLC (NYSE: MDT), Baxter International Inc. (NYSE: BAX)

The drop in sales witnessed in the medical device and technology markets from 2014 to 2015 resulted in 12 out the 20 largest companies in the market to have negative growth, according to Evaluate's research. This in turn caused several "mega mergers" and cost cuts. In the first half of 2016 mergers and acquisitions activities dropped nearly 80%, indicating that consolidation will no longer be an issue to worry about and partially due to resumed growth. Ian Strickland, EvaluateMedTech product manager said, "The device industry is growing reasonably rapidly, and the calming of the M&A scene does not pose a problem for the expected growth."

A small company making noise in this sector, Medovex Corp. (NASDAQ: MDVX) is biomedical device company with the mission of acquiring and developing a portfolio of potentially ground breaking medical technology products. According to the company, they focus on products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at a much lower cost than other currently available treatments.

Recently on October 13th Medovex Corp. announced that the company successfully exhibited its' DenerveX System during EuroSpine 2016 Tradeshow last week in Berlin, Germany. The event marked the official opening of the Company's European Distribution Center in Berlin. The new distribution service headquarters will function as a commercial hub for all European distributors, as well as other customer and technical support services, while international operations center and the company's global operational headquarters will remain in Atlanta, Georgia.

Patrick Kullmann, President and COO for Medovex Corp., said in a statement, "We consider EuroSpine 2016 in Berlin our 'pre-launch' meeting leading up to what is expected to be an eventual formal CE Marking. In particular, we were very pleased to see visiting surgeons and distributors from more than 25 countries, and from all continents, at our booth, along with existing and new potential distributors visiting with us."

Boston Scientific Corporation (NYSE: BSX) is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The company manufactures devices such as defibrillators, direct visualization systems, remote monitoring devices, and many more. Earlier this August, Boston Scientific has announced the FDA approval of the EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System.

Zimmer Biomet Holdings Inc. (NYSE: ZBH) is engaged designing, manufacturing and marketing a wide range of medically relevant products, including orthopaedic reconstructive products, sports medicine, biologics, extremities and trauma products, as well as spine and bone healing, and more. Recently the company announced the acquisition of RespondWell, an award-winning telerehabilitation technology designed to provide clinician-supervised post-surgical physical therapy in the comfort of a patient's home.

Medtronic PLC (NYSE: MDT) is a medical technology and services company focused on development, manufacturing and marketing of medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. This October the Medtronic announced the an FDA approval and U.S. launch of the CoreValve(TM) Evolut(TM) R 34 mm valve-the largest sized transcatheter aortic valve replacement system available in the U.S. The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at high or extreme risk for surgery.

Baxter International Inc. (NYSE: BAX) owns a portfolio of essential renal and hospital products, including home, acute and in-center dialysis, sterile intravenous (IV) solutions, infusion systems and more. The company also provides products and services related to pharmacy compounding, and drug formulation. This month Baxter announced the global launch of HDx enabled by THERANOVA, a new type of hemodialysis therapy that provides high performance treatments with integration into existing healthcare infrastructure. Baxter will launch HDx enabled by THERANOVA in Australia, New Zealand, France, Germany, Switzerland and Belgium this year.

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated twelve thousand dollars for financial news dissemination and pr services by a non-affiliated third party for medovex corp. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information: Media Contact: Danny A, info@financialbuzz.com , +1-877-601-1879 URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Hospital Safety Grades Released, Revealing How...
S
Eisai Initiates Phase 2 Clinical Trial to Evaluate...